- Trial phase
- Approved
- Time to market
- Already on the market. CNJ-016 received initial FDA approval in 2005 and has been commercially available for nearly two decades.
- Why 4/10
- CNJ-016 is already FDA-approved and commercially marketed (since 2005) with no pending regulatory decision or pivotal readout in the next 12 months. Its revenue comes from periodic U.S. government contract awards under an existing 10-year framework, not from a binary catalyst. Therefore the impact score is capped at 4.
CNJ-016 is already approved and generating revenue through government stockpile contracts. Watch for future ASPR contract option exercises under the existing 10-year agreement and any changes in U.S. biodefense spending priorities, which directly drive the drug's revenue stream. The next catalyst is not a binary regulatory event but continued contract awards, making this a slow-burn commercial story rather than a binary biotech bet.
Price Chart
Executive Summary
CNJ-016 (Vaccinia Immune Globulin Intravenous, VIGIV) is an FDA-approved plasma-derived antibody therapy for treating complications from smallpox vaccination. First approved in 2005, it is manufactured by Emergent BioSolutions (NYSE: EBS) and sold almost exclusively to the U.S. government for the Strategic National Stockpile under a 10-year contract valued at approximately $535 million. The drug is a mature, approved product with no pending regulatory binary; its revenue depends on periodic government contract options being exercised. In 2026, the company secured $54 million in new U.S. orders and additional international business. However, Q3 2026 results showed smallpox medical countermeasure revenues (including CNJ-016) fell 68% year-over-year, contributing to a 52% total revenue decline and a post-earnings stock drop of roughly 18.6%.
How It Works
CNJ-016 (VIGIV) is a sterile solution containing high levels of antibodies (immune globulins) derived from the blood plasma of healthy donors who were previously vaccinated against smallpox. When infused into a patient, these antibodies provide passive immunity by neutralizing the vaccinia virus, helping the body fight off serious complications that can arise from the smallpox vaccine itself, such as severe skin infections or progressive viral illness.
Trial Status
CNJ-016 is FDA-approved (BLA 125109, 2005) and commercially marketed. A Phase 4 post-marketing study (NCT01374984) is ongoing to verify clinical benefits in patients with smallpox vaccination complications. An Expanded Access IND protocol also exists for treatment of orthopoxvirus infections.
The Two-Sided Case
Upcoming Catalysts
- Future U.S. government contract option exercises under the existing 10-year ASPR agreement (75A50119C00037)
- Potential expanded use under the orthopoxvirus Expanded Access IND protocol
- Any changes in U.S. biodefense funding or smallpox preparedness policy
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Emergent BioSolutions Inc. 8-K EBS ·Originating report